Andrea Antinori

Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani — Italy

Immunology and Microbiology · Life Sciences

88h-index38.7kcitations1.1kworks3.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HIV Research and Treatment(437), HIV/AIDS drug development and treatment(419), HIV/AIDS Research and Interventions(353), HIV-related health complications and treatments(162), Pneumocystis jirovecii pneumonia detection and treatment(103)

Publications1.0k total

Improved HIV-1 Subtyping Accuracy Using near Full-Length Sequencing: A Comparison of Common Tools
International Journal of Molecular Sciences·2025Open Access
Integrase versus protease inhibitor therapy in advanced HIV disease (LAPTOP): a multicountry, randomised, open-label, non-inferiority trial
The Lancet Infectious Diseases·2025Open Access
Mental health, stigma and risk perception among early adopters of HIV PrEP with LA Cabotegravir in Italy: a multicenter cross-sectional and implementation study
International Journal of Infectious Diseases·2025Open Access
Quality of Life and Treatment Satisfaction in People with HIV Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide: Pooled Analysis from Observational Cohort Studies
Infectious Diseases and Therapy·2025Open Access
Inflammatory Milieu and Specific T-Cell Response Observed Three Months and One Year After SARS-CoV-2 Infection in Long COVID Subjects
International Journal of Molecular Sciences·2025Open Access
Long-term trajectories of hepatic and metabolic biomarkers after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral therapy-experienced people with HIV with and without hepatic coinfection: Data from the ICONA cohort
International Journal of Infectious Diseases·2025Open Access
Early results from implementation of HIV pre-exposure prophylaxis (PrEP) with long-acting injectable cabotegravir for people with barriers to oral strategies, Italy, December 2024 to August 2025
Eurosurveillance·2025· 1 citedOpen Access
Primary Aggressive Oral Lymphomas (PAOL): A Narrative Review of Diagnosis, Molecular Features, Therapeutic Approaches, and the Integrated Role of Dentists and Hematologists
Cancers·2025Open Access
Time to anti-cancer treatment resumption after SARS-CoV-2 infection in patients with active haematological diseases undergoing combined antiviral treatments
Journal of Antimicrobial Chemotherapy·2025Open Access
Effectiveness of first-line lamivudine/dolutegravir antiretroviral therapy in persons with HIV: real-life data from the ICONA Foundation cohort
Journal of Antimicrobial Chemotherapy·2025· 1 citedOpen Access
Prolonged clinical monitoring of cognitive performance and psychiatric symptoms among PACS
2025Open Access
HIV Oral Pre-exposure Prophylaxis Effectiveness, Adherence, and Discontinuation in an Italian Multicentric Access Program: ItaPrEP Study
Open Forum Infectious Diseases·2025· 7 citedOpen Access
Humoral and T-cell responses following MVA-BN booster vaccination against mpox virus clades Ib and IIb
Journal of Infection·2025· 1 citedOpen Access
A Single-Center Retrospective Study on Early Treatment for COVID-19 in Solid Organ Transplant Recipients During the Omicron Era: Outcomes and SARS-CoV-2 Viral Kinetics
Microorganisms·2025Open Access
All-cause and Cause-specific Mortality in People With HIV in Italy in 1997–2022: Data From the Icona Cohort
Open Forum Infectious Diseases·2025· 1 citedOpen Access
Risk of clinical events in virologically suppressed people with HIV switching to a two-drug regimen vs. remaining on a three-drug regimen: a target trial emulation
EClinicalMedicine·2025· 2 citedOpen Access
Switching to bictegravir/emtricitabine/tenofovir alafenamide from efavirenz/emtricitabine/tenofovir disoproxil in virologically suppressed people with HIV: findings from a non-randomized clinical trial (EBONY study)
International Journal of Infectious Diseases·2025Open Access
Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort
Journal of Antimicrobial Chemotherapy·2025· 5 citedOpen Access
Expression of HCMV-Encoded miRNA in Subjects Acutely Coinfected with HIV: Correlation with Inflammation and Immune Activation
International Journal of Molecular Sciences·2025Open Access
The Genetic and Epigenetic Alterations of Plasmablastic Lymphoma: A Narrative Review
Cancers·2025· 1 citedOpen Access
page 1 of 52Next →

Frequent Co-authors

Antonella d’Arminio Monforte(14), Antonella Cingolani(14), Adriana Ammassari(13), Andrea De Luca(11), Rita Murri(9), Emanuele Nicastri(7), Giuseppe Ippolito(7), Paola Cinque(5), Maria Paola Trotta(5), Albert W. Wu(5), Cristina Mussini(5), Alessandra Vergori(5), Luigi Maria Larocca(5), Andrew Phillips(4), Enrico Girardi(4), Pasquale Narciso(4), Francesco Castelli(4), Caroline Sabin(4), Roberto Cauda(4), Fabrizio Palmieri(4)